---
figid: PMC9691845__fendo-13-1027237-g001
figtitle: Review on phytochemical and pharmacological facets of tropical ethnomedicinal
  plants as reformed DPP-IV inhibitors to regulate incretin activity
organisms:
- Mus musculus
- Rattus norvegicus
- Terminalia anogeissiana
- Pterocarpus marsupium
- Psidium guajava
- Withania somnifera
- Annona muricata
- Coffea arabica
- Rheum palmatum
- Marsilea quadrifolia
- Ipomoea nervosa
- Vitis thunbergii
- Terminalia arjuna
- Withania coagulans
- Lippia graveolens
- Ocimum tenuiflorum
- Acacia auriculiformis
- Commiphora mukul
- Rubus plicatus
- Heritiera fomes
- Pilea microphylla
- Punica granatum
- Pyrus communis
- Castanospermum australe
- Syzygium cumini
- Coptis chinensis
- Helichrysum arenarium
- Parabacteroides chongii
- Citrus limon
- Citrus sinensis
- Palmaria palmata
- Amaranthus hypochondriacus
- Phyllanthus emblica
- Mangifera indica
- Aloe vera
- Eucalyptus camaldulensis
- Eucalyptus globulus
- Corymbia citriodora
- Morus alba
- Amaranthus caudatus
- Fagopyrum esculentum
- Theobroma cacao
- Momordica charantia
- Brassica oleracea
- Citrus maxima
- Moringa oleifera
- Malus domestica
- Prunus dulcis
- Cicer arietinum
- Glycine max
- Lens culinaris
- Lupinus albus
- Phaseolus vulgaris
- Salvia rosmarinus
- Leonurus sibiricus
- Gymnema sylvestre
- Cullen corylifolium
- Citrus aurantium
- Morinda citrifolia
- Camellia sinensis
- Avena sativa
- Hordeum vulgare
- Pueraria tuberosa
- Allium sativum
- Schisandra chinensis
- Ferula assa-foetida
- Aureobasidium pullulans
- Berberis aristata
- Ficus religiosa
- Pleurolobus gangeticus
- Aegle marmelos
- Gynura bicolor
- Trigonella foenum-graecum
- Danio rerio
- Hedera nepalensis
- Fagonia cretica
- Homo sapiens
- NA
- NA
- NA
- NA
- NA
- NA
- NA
- NA
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9691845
filename: fendo-13-1027237-g001.jpg
figlink: /pmc/articles/PMC9691845/figure/f1/
number: F1
caption: An overview of the impact of dipeptidyl peptidase (DPP)-IV inhibitors on
  the kidney and the insulin signaling pathways. The key aspects of the insulin signaling
  pathway, such as insulin binding, signal cascade, exocytosis, and glucose entry,
  are presented. DPP-IV inhibitors (DPP-IVis) are non-insulin glucose-lowering agents
  that are members of the incretin family. They are able to improve glycemic control
  while maintaining an acceptable level of safety. In individuals with chronic kidney
  disease, these medications are associated with a minimal risk of hypoglycemia, no
  weight gain, and good overall tolerability. The results of clinical trials are still
  up for debate, even though several experimental and clinical research point to the
  possibility that DPP-IVis may exert considerable pleiotropic effects, particularly
  on the kidneys. The figure was created with BioRender.com.
papertitle: A review on phytochemical and pharmacological facets of tropical ethnomedicinal
  plants as reformed DPP-IV inhibitors to regulate incretin activity.
reftext: Srishti Chhabria, et al. Front Endocrinol (Lausanne). 2022;13:1027237.
year: '2022'
doi: 10.3389/fendo.2022.1027237
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: dipeptidyl peptidase-IV | insulin resistance | incretin | polyherbal formulations
  | antioxidants | hormonal disorder
automl_pathway: 0.9109293
figid_alias: PMC9691845__F1
figtype: Figure
redirect_from: /figures/PMC9691845__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9691845__fendo-13-1027237-g001.html
  '@type': Dataset
  description: An overview of the impact of dipeptidyl peptidase (DPP)-IV inhibitors
    on the kidney and the insulin signaling pathways. The key aspects of the insulin
    signaling pathway, such as insulin binding, signal cascade, exocytosis, and glucose
    entry, are presented. DPP-IV inhibitors (DPP-IVis) are non-insulin glucose-lowering
    agents that are members of the incretin family. They are able to improve glycemic
    control while maintaining an acceptable level of safety. In individuals with chronic
    kidney disease, these medications are associated with a minimal risk of hypoglycemia,
    no weight gain, and good overall tolerability. The results of clinical trials
    are still up for debate, even though several experimental and clinical research
    point to the possibility that DPP-IVis may exert considerable pleiotropic effects,
    particularly on the kidneys. The figure was created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Wdtc1
  - Abcg1
  - Lepr
  - Slc2a4
  - Gcg
  - Ehmt1
  - Zglp1
  - SLC2A4
  - GCG
  - GLP1R
  - ZGLP1
  - EHMT1
  - DPP4
  - FAP
  - tup
  - AP-2alpha
  - alpha-Spec
  - bam
  - alphaTry
  - beta-Spec
  - betaTub56D
  - betaTry
  - anon-70Da
  - wat
  - 'On'
  - GlyP
---
